



- (51) **International Patent Classification:**  
G01N 33/53 (2006.01)
- (21) **International Application Number:**  
PCT/US2012/056961
- (22) **International Filing Date:**  
24 September 2012 (24.09.2012)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**  
61/538,096 22 September 2011 (22.09.2011) US
- (71) **Applicant:** EXPRESSION PATHOLOGY, INC.  
[US/US]; 9620 Medical Center Drive, Suite 100, Rockville, MD 20850 (US).
- (72) **Inventors:** KRIZMAN, David, B.; 24305 Welsh Road, Gaithersburg, MD 20882 (US). HEMBROUGH, Todd; 24336 Newberry Road, Gaithersburg, MD 20880 (US). THYPARAMBIL, Sheeno; 3730 Singleton Terrace, Frederick, MD 21704 (US). LIAO, Wei-Liao; 1112 Shannon Place, Herndon, VA 20170 (US).
- (74) **Agent:** BOOTH, Paul, M.; Perkins Coie LLP, 1201 Third Avenue, Suite 4800, Seattle, WA 98101-3099 (US).
- (81) **Designated States** (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM,

AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

- (84) **Designated States** (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

**Published:**

- without international search report and to be republished upon receipt of that report (Rule 48.2(g))
- with sequence listing part of description (Rule 5.2(a))

(54) **Title:** MRM/SRM ASSAY FOR DEATH RECEPTOR 5 PROTEIN

(57) **Abstract:** Specific peptides, and derived ionization characteristics of those peptides from Death Receptor 5 (DR5) protein are provided that are particularly advantageous for quantifying the DR5 protein directly in biological samples that have been fixed in formalin by the method of Selected Reaction Monitoring / Multiple Reaction Monitoring (SRM/MRM) mass spectrometry. Such biological samples are chemically preserved and fixed wherein the biological sample is selected from tissues and cells treated with formaldehyde containing agents/fixatives including formalin-fixed tissue/cells, formalin-fixed/paraffin embedded (FFPE) tissue/cells, FFPE tissue blocks and cells from those blocks, and tissue culture cells that have been formalin fixed and or paraffin embedded. A protein sample is prepared from a biological sample using the Liquid Tissue™ reagents and protocol, and the DR5 protein are quantitated in the Liquid Tissue™ sample by the method of SRM/MRM mass spectrometry by quantitating in the protein sample at least one or more of the peptides described for one or more of the DR5 protein. These peptides can be quantitated if they reside in a modified or in an unmodified form. An example of a modified form of a DR5 peptide is phosphorylation of a tyrosine, threonine, serine, and/or other amino acid residues within the peptide sequence



## MRM/SRM Assay for Death Receptor 5 Protein

This application claims the benefit of U.S. Provisional Application No. 61/538,096, filed September 22, 2011, entitled "MRM/SRM Assay for Death Receptor 5 Protein," the content of which are hereby incorporated by referenced in their entirety.

### 5 Introduction

Specific peptides derived from subsequences of the Death Receptor 5 (DR5) protein are provided. The peptide sequences and fragmentation/transition ions for each peptide are particularly useful in a mass spectrometry-based Selected Reaction Monitoring (SRM) assay, which can also be referred to as a Multiple Reaction Monitoring (MRM) assay. Such assays are referred to herein as SRM/MRM. The use of peptides for quantitative SRM/MRM analysis of the DR5 proteins is described.

This SRM/MRM assay can be used to measure *relative* or *absolute* quantitative levels of one or more of the specific peptides from the DR5 protein. This provides a means of measuring the amount of the DR5 protein in a given protein preparation obtained from a biological sample by mass spectrometry.

More specifically, the SRM/MRM assay can measure these peptides directly in complex protein lysate samples prepared from cells procured from patient tissue samples, such as formalin fixed cancer patient tissue. Methods of preparing protein samples from formalin-fixed tissue are described in U.S. Patent No. 7,473,532, the contents of which are hereby incorporated by reference in their entirety. The methods described in U.S. Patent No. 7,473,532 may conveniently be carried out using Liquid Tissue™ reagents and protocol available from OncoPlexDx (formerly Expression Pathology Inc., Rockville, MD).

Results from the SRM/MRM assay, where the proteins are analyzed individually or simultaneously, can be used to correlate accurate and precise quantitative amounts of these proteins within specific tissue samples (e.g., cancer tissue sample) of the patient or subject from whom the tissue (biological sample) was collected and preserved. This not only provides diagnostic information about the cancer, but also permits a physician or other medical professional to determine appropriate therapy for the cancer patient. Such an assay that provides diagnostically and therapeutically important information about levels of protein expression in a diseased tissue or other patient sample is termed a "companion diagnostic" assay. For example, such an assay can be designed to diagnose the stage or degree of a cancer and determine a therapeutic agent to which a patient is most likely to respond.

## Summary

The assays described herein measure *relative or absolute* levels of specific unmodified peptides from the DR5 protein and also can measure *absolute or relative* levels of specific modified peptides from the DR5 protein. Examples of modifications include phosphorylated amino acid residues (*e.g.* phosphotyrosine, phosphoserine and phosphothreonine) and glycosylated amino acid residues (*e.g.* glycosylated asparagine residues) that are present on the peptides.

*Relative* quantitative levels of the DR5 protein are determined by the SRM/MRM methodology, for example, by comparing SRM/MRM signature peak areas (*e.g.*, signature peak area or integrated fragment ion intensity) of an individual DR5 peptide in different samples. Alternatively, it is possible to compare multiple SRM/MRM signature peak areas for multiple DR5 signature peptides, where each peptide has its own specific SRM/MRM signature peak, to determine the relative DR5 protein content in one biological sample with the DR5 protein content in one or more additional or different biological samples. In this way, the amount of a particular peptide, or peptides, from the DR5 protein, and therefore the amount of the DR5 protein, is determined relative to the same DR5 peptide, or peptides, across 2 or more biological samples under the same experimental conditions. In addition, relative quantitation can be determined for a given peptide, or peptides, from the DR5 protein within a single sample by comparing the signature peak area for that peptide by SRM/MRM methodology to the signature peak area for another and different peptide, or peptides, from a different protein, or proteins, within the same protein preparation from the biological sample. In this way, the amount of a particular peptide from the DR5 protein, and therefore the amount of the DR5 protein, is determined relative one to another within the same sample. These approaches generate quantitation of an individual peptide, or peptides, from the DR5 protein to the amount of another peptide, or peptides, between samples and within samples wherein the amounts as determined by peak area are relative one to another, regardless of the absolute weight to volume or weight to weight amounts of the DR5 peptide in the protein preparation from the biological sample. Relative quantitative data about individual signature peak areas between different samples are normalized to the amount of protein analyzed per sample. Relative quantitation can be performed across many peptides from multiple proteins and the DR5 protein simultaneously in a single sample and/or across many samples to gain insight into relative protein amounts, one peptide/protein with respect to other peptides/proteins.

*Absolute* quantitative levels of the DR5 protein are determined by, for example, the SRM/MRM methodology whereby the SRM/MRM signature peak area of an individual peptide

from the DR5 protein in one biological sample is compared to the SRM/MRM signature peak area of an exogenously added "spiked" internal standard. In one embodiment, the internal standard is a synthetic version of the same exact DR5 peptide that contains one or more amino acid residues labeled with one or more heavy isotopes. Suitable isotope-labeled internal standards are synthesized so that, when analyzed by mass spectrometry, each standard generates a predictable and consistent SRM/MRM signature peak that is different and distinct from the native DR5 peptide signature peak and which can be used as a comparator peak. Thus, when the internal standard is spiked in a known amount into a protein preparation from a biological sample and analyzed by mass spectrometry, the SRM/MRM signature peak area of the native peptide from the sample can be compared to the SRM/MRM signature peak area of the internal standard peptide. This numerical comparison provides either the absolute molarity and/or absolute weight of the native peptide present in the original protein preparation from the biological sample. Absolute quantitative data for fragment peptides are displayed according to the amount of protein analyzed per sample. Absolute quantitation can be performed across many peptides, and thus proteins, simultaneously in a single sample and/or across many samples to gain insight into absolute protein amounts in individual biological samples and in entire cohorts of individual samples.

The SRM/MRM assay method can be used to aid diagnosis of the stage of cancer, for example, directly in patient-derived tissue, such as formalin fixed tissue, and to aid in determining which therapeutic agent would be most advantageous for use in treating that patient. Cancer tissue that is removed from a patient either through surgery, such as for therapeutic removal of partial or entire tumors, or through biopsy procedures conducted to determine the presence or absence of suspected disease, is analyzed to determine whether or not a specific protein, or proteins, and which forms of proteins, are present in that patient tissue. Moreover, the expression level of a protein, or multiple proteins, can be determined and compared to a "normal" or reference level found in healthy tissue. Normal or reference levels of proteins found in healthy tissue may be derived from, for example, the relevant tissues of one or more individuals that do not have cancer. Alternatively, normal or reference levels may be obtained for individuals with cancer by analysis of relevant tissues not affected by the cancer.

Alternatively, normal or reference levels may be obtained for individuals with cancer by analysis of relevant tissues not affected by the cancer. Assays of protein levels (e.g., DR5 levels) can also be used to diagnose the stage of cancer in a patient or subject diagnosed with cancer by employing the DR5 levels. Levels of an individual DR5 peptide is defined as molar amount of the peptide determined by the SRM/MRM assay per total amount of protein lysate analyzed. Information regarding DR5 can thus be used to aid in determining stage or grade of a cancer by

correlating the level of the DR5 protein (or fragment peptides of the DR5 protein) with levels observed in normal tissues.

Assays of protein levels (e.g., DR5 levels) can also be used to diagnose the stage of cancer in a patient or subject diagnosed with cancer by employing the DR5 levels. Levels or  
5 amounts of proteins or peptides can be defined as the quantity expressed in moles, mass or weight of a protein or peptide determined by the SRM/MRM assay. The level or amount may be normalized to total the level or amount of protein or another component in the lysate analyzed (e.g., expressed in micromoles/microgram of protein or micrograms /microgram of protein). In addition, the level or amount of a protein or peptide may be determined on volume basis,  
10 expressed, for example, in micromolar or nanograms/microliter. The level or amount of protein or peptide as determined by the SRM/MRM assay can also be normalized to the number of cells analyzed. Information regarding DR5 can thus be used to aid in determining stage or grade of a cancer by correlating the level of the DR5 protein (or fragment peptides of the DR5 protein) with levels observed in normal tissues.

15 Once the stage and/or grade, and/or DR5 protein expression characteristics of the cancer has been determined, that information can be matched to a list of therapeutic agents (chemical and biological) developed to specifically treat cancer tissue that is characterized by, for example, abnormal expression of the protein or protein(s) (e.g., DR5) that were assayed. Matching information from an DR5 protein assay to a list of therapeutic agents that specifically targets, for  
20 example, the DR5 protein or cells/tissue expressing the protein, defines what has been termed a *personalized medicine* approach to treating disease. The assay methods described herein form the foundation of a *personalized medicine* approach by using analysis of proteins from the patient's own tissue as a source for diagnostic and treatment decisions. The DR5 protein can be analyzed individually or in combination with other proteins in a personalized medicine approach  
25 to diagnosing and treating cancer.

These and other aspects of the present disclosure will become apparent to the skilled person in view of the description set forth below.

### Detailed Description

30 The Selected Reaction Monitoring/Multiple Reaction Monitoring (SRM/MRM) assay can be used to measure relative or absolute quantitative levels of one or more of the specific peptides from the DR5 protein, individually, in combinations, or simultaneously, and therefore provide a means of measuring the amount of the DR5 protein in a given protein preparation obtained from a biological sample by mass spectrometry.

More specifically, the SRM/MRM assay can measure these peptides directly in complex protein lysate samples prepared from cells procured from patient tissue samples, such as formalin fixed cancer patient tissue. Methods of preparing protein samples from formalin fixed tissue are described in U.S. Patent No. 7,473,532, the contents of which are hereby incorporated  
5 by references in their entireties. The methods described in U.S. Patent No. 7,473,532 may conveniently be carried out using Liquid Tissue™ reagents and protocol available from OncoPlexDx (formerly Expression Pathology Inc., Rockville, MD).

The most widely and advantageously available form of tissues from cancer patient tissue is formalin fixed, paraffin embedded tissue. Formaldehyde/formalin fixation of surgically  
10 removed tissue is by far and away the most common method of preserving cancer tissue samples worldwide and is the accepted convention for standard pathology practice. Aqueous solutions of formaldehyde are referred to as formalin. "100%" formalin consists of a saturated solution of formaldehyde (this is about 40% by volume or 37% by mass) in water, with a small amount of stabilizer, usually methanol to limit oxidation and degree of polymerization. The most common  
15 way in which tissue is preserved is to soak whole tissue for extended periods of time (8 hours to 48 hours) in aqueous formaldehyde, commonly termed 10% neutral buffered formalin, followed by embedding the fixed whole tissue in paraffin wax for long term storage at room temperature. Thus molecular analytical methods to analyze formalin fixed cancer tissue will be the most accepted and heavily utilized methods for analysis of cancer patient tissue.

In principle, any predicted peptide derived from the DR5 protein, prepared for example  
20 by digesting with a protease of known specificity (*e.g.* trypsin), can be used as a surrogate reporter to determine the abundance of DR5 protein in a sample using a mass spectrometry-based SRM/MRM assay. Similarly, any predicted peptide sequence containing an amino acid residue at a site that is known to be potentially modified in the DR5 protein also might  
25 potentially be used to assay the extent of modification of the DR5 protein in a sample.

According to one embodiment, DR5 fragment peptides may be generated in a variety of ways including using the Liquid Tissue™ protocol described in US Patent 7,473,532. The Liquid Tissue™ protocol and reagents produce peptide samples suitable for mass spectroscopic analysis from formalin fixed paraffin embedded tissue by proteolytic digestion of the proteins in  
30 the tissue/biological sample. Suitable reagents and protocols also are commercially available from OncoPlexDx (formerly Expression Pathology Inc., Rockville, MD).

In the Liquid Tissue™ protocol the tissue/biological sample is heated in a buffer for an extended period of time (*e.g.*, from about 80° C to about 100° C for a period of time from about 10 minutes to about 4 hours) to reverse or release protein cross-linking. The buffer employed is

a neutral buffer, (e.g., a Tris-based buffer, or a buffer containing a detergent). Following heat treatment the tissue/biological sample is treated with one or more proteases including, but not limited to, trypsin, chymotrypsin, pepsin, and endoproteinase Lys-C for a time sufficient to disrupt the tissue and cellular structure of said biological sample and to liquefy the sample.

5 Exemplary conditions for the protease treatment are from 30 minutes to 24 hours at a temperature from 37° C to 65° C). Advantageously, endoproteases, and particularly combinations of two or three endoproteases, used either simultaneously or sequentially, are employed to liquefy the sample. For example, suitable combinations of proteases can include, but are not limited to, combinations of trypsin, endoproteinase Lys-C and chemotrypsin, such as  
10 trypsin and endoproteinase Lys-C. The result of the heating and proteolysis is a liquid, soluble, dilutable biomolecule lysate. Advantageously, this liquid lysate is free of solid or particulate matter that can be separated from the lysate by centrifugation.

Surprisingly, it was found that many potential peptide sequences from the DR5 protein are unsuitable or ineffective for use in mass spectrometry-based SRM/MRM assays for reasons  
15 that are not immediately evident. As it was not possible to predict the most suitable peptides for MRM/SRM assay, it was necessary to experimentally identify modified and unmodified peptides in actual Liquid Tissue™ lysates to develop a reliable and accurate SRM/MRM assay for the DR5 protein. While not wishing to be bound by any theory, it is believed that some peptides might, for example, be difficult to detect by mass spectrometry because they do not ionize well  
20 or produce fragments that are not distinct from those generated from other proteins. Peptides may also fail to resolve well in separation (e.g., liquid chromatography), or may adhere to glass or plastic ware, which leads to erroneous results in the SRM/MRM assay..

DR5 peptides found in various embodiments of this disclosure (for example, Tables 1 and 2 below) were derived from the DR5 protein by protease digestion of all the proteins within  
25 a complex Liquid Tissue™ lysate prepared from cells procured from formalin fixed cancer tissue. Unless noted otherwise, in each instance the protease was trypsin. The Liquid Tissue™ lysate was then analyzed by mass spectrometry to determine those peptides derived from the DR5 protein that are detected and analyzed by mass spectrometry. Identification of a specific preferred subset of peptides for mass-spectrometric analysis is based on: 1) experimental  
30 determination of which peptide or peptides from a protein ionize in mass spectrometry analyses of Liquid Tissue™ lysates, and 2) the ability of the peptide to survive the protocol and experimental conditions used in preparing a Liquid Tissue™ lysate. This latter property extends not only to the amino acid sequence of the peptide but also to the ability of a modified amino acid residue within a peptide to survive in modified form during the sample preparation.

Protein lysates from cells procured directly from formalin (formaldehyde) fixed tissue were prepared using the Liquid Tissue™ reagents and protocol. This entails collecting cells into a sample tube via tissue microdissection followed by heating the cells in the Liquid Tissue™ buffer for an extended period of time. Once the formalin-induced cross linking has been negatively affected, the tissue/cells are then digested to completion in a predictable manner using a protease such as, trypsin. The skilled artisan will recognize that other proteases, and in particular, endoproteases may be used in place of, or in addition to, trypsin. Each protein lysate was used to prepare a collection of peptides by digestion of intact polypeptides with the protease or protease combination. Each Liquid Tissue™ lysate was analyzed (*e.g.*, by ion trap mass spectrometry) to perform multiple global proteomic surveys of the peptides where the data was presented as identification of as many peptides as could be identified by mass spectrometry from all cellular proteins present in each protein lysate. An ion trap mass spectrometer or another form of a mass spectrometer that is capable of performing global profiling for identification of as many peptides as possible from a single complex protein/peptide lysate may be employed. Ion trap mass spectrometers may, however, be the best type of mass spectrometer for conducting global profiling of peptides. Although SRM/MRM assays can be developed and performed on any type of mass spectrometer, including a MALDI, ion trap, or triple quadrupole, an instrument platform for SRM/MRM assay is often considered to be a triple quadrupole instrument platform.

Once as many peptides as possible were identified in a single mass spectrometric analysis of a single lysate under the conditions employed, then the list of identified peptides was collated and used to determine the proteins that were detected in that lysate. This process was repeated for multiple Liquid Tissue™ lysates, and the very large list of peptides was collated into a single dataset. The resulting dataset represents the peptides that can be detected in the type of biological sample that was analyzed (after protease digestion), and specifically in a Liquid Tissue™ lysate of the biological sample, and thus includes the peptides for specific proteins, such as for example the DR5 protein.

In one embodiment, the DR5 tryptic peptides identified as useful in the determination of absolute or relative amounts of the DR5 protein include one or more, two or more, or three of the peptides of SEQ ID NO:1, SEQ ID NO:2, and SEQ ID NO:3, each of which are shown in Table 1. Each of those peptides was detected by mass spectrometry in Liquid Tissue™ lysates prepared from formalin fixed, paraffin embedded tissue. Thus, each of the peptides in Table 1, or any combination of those peptides (*e.g.*, one or more, two or more, or three of those peptides recited in Table 1) are candidates for use in quantitative SRM/MRM assay for the DR5 protein in human biological samples, including directly in formalin fixed patient tissue. Table 2 shows additional information regarding the peptides shown in Table 1.

**Table 1**

SEQ ID	Peptide sequence
SEQ ID NO: 1	LLVPANEGDPTETLR
SEQ ID NO: 2	IEDHLLSSGK
SEQ ID NO: 3	DASVHTLLDALETGER

**Table 2**

SEQ ID	Peptide sequence	Mono Isotopic Mass	Precursor Charge State	Precursor m/z	Transition m/z	Ion Type
SEQ ID NO: 1	LLVPANEGDPTETLR	1623.847	2	812.931	716.393	y6
			2	812.931	888.442	y8
			2	812.931	1017.484	y9
			2	812.931	1131.527	y10
			2	812.931	1299.617	y12
SEQ ID NO: 2	IEDHLLSSGK	1097.572	2	549.793	491.282	y5
			2	549.793	604.366	y6
			2	549.793	741.425	y7
			2	549.793	856.452	y8
SEQ ID NO: 3	DASVHTLLDALETGER	1838.937	2	920.4749756	888.478	y8
			2	920.4749756	1003.505	y9
			2	920.4749756	1116.589	y10
			2	920.4749756	1229.673	y11

5

The DR5 tryptic peptides listed in Table 1 include those detected from multiple Liquid Tissue™ lysates of multiple different formalin fixed tissues of different human organs including prostate, colon, and breast. Each of those peptides is considered useful for quantitative SRM/MRM assay of the DR5 protein in formalin fixed tissue. Further data analysis of these experiments indicated no preference is observed for any specific peptides from any specific organ site. Thus, each of these peptides is believed to be suitable for conducting SRM/MRM assays of the DR5 protein on a Liquid Tissue™ lysate from any formalin fixed tissue originating from any biological sample or from any organ site in the body.

10

15

One consideration for conducting an SRM/MRM assay is the type of instrument that may be employed in the analysis of the peptides. Although SRM/MRM assays can be developed and performed on any type of mass spectrometer, including a MALDI, ion trap, or triple quadrupole, the most advantageous instrument platform for SRM/MRM assay is often considered to be a triple quadrupole instrument platform. That type of a mass spectrometer may be considered to be the most suitable instrument for analyzing a single isolated target peptide within a very

20

complex protein lysate that may consist of hundreds of thousands to millions of individual peptides from all the proteins contained within a cell.

In order to most efficiently implement an SRM/MRM assay for each peptide derived from the DR5 protein it is desirable to utilize information in addition to the peptide sequence in the analysis. That additional information may be used in directing and instructing the mass spectrometer (e.g. a triple quadrupole mass spectrometer), to perform the correct and focused analysis of specific targeted peptide(s), such that the assay may be effectively performed.

The additional information about target peptides in general, and about specific DR5 peptides, may include one or more of the mono isotopic mass of the peptide, its precursor charge state, the precursor m/z value, the m/z transition ions, and the ion type of each transition ion. Additional peptide information that may be used to develop an SRM/MRM assay for the DR5 protein is shown in Table 2.

The methods described below can be used to: 1) identify candidate peptides from the DR5 protein that can be used for a mass spectrometry-based SRM/MRM assay for the DR5 protein, 2) develop individual SRM/MRM assays, or multiplexed assays, for target peptides from the DR5 protein in order to correlate to cancer, and 3) apply quantitative DR5 assays to cancer diagnosis and/or choice of optimal therapy for cancer.

### Assay Methods

- I. Identification of SRM/MRM candidate fragment peptides for the DR5 protein:
  - a. Prepare a Liquid Tissue™ protein lysate from a formalin fixed biological sample using a protease or proteases, (that may or may not include trypsin), to digest proteins
  - b. Analyze all protein fragments in the Liquid Tissue™ lysate on an ion trap tandem mass spectrometer and identify all fragment peptides from the DR5 protein, where individual fragment peptides do not contain any peptide modifications such as phosphorylations or glycosylations
  - c. Analyze all protein fragments in the Liquid Tissue™ lysate on an ion trap tandem mass spectrometer and identify all fragment peptides from the DR5 protein that carry peptide modifications such as for example phosphorylated or glycosylated residues
  - d. All peptides generated by a specific digestion method from the entire, full length DR5 protein potentially can be measured, but preferred peptides used for development of the SRM/MRM assay are those that are identified by mass spectrometry directly in a

complex Liquid Tissue™ protein lysate prepared from a formalin fixed biological sample

- e. Peptides that are specifically modified (phosphorylated, glycosylated, etc.) in patient tissue and which ionize, and thus detected, in a mass spectrometer when analyzing a Liquid Tissue™ lysate from a formalin fixed biological sample are identified as candidate peptides for assaying peptide modifications of the DR5 protein

## II. Mass Spectrometry Assay for Fragment Peptides from DR5 protein

- a. SRM/MRM assay on a triple quadrupole mass spectrometer for individual fragment peptides identified in a Liquid Tissue™ lysate is applied to peptides from the DR5 protein

i. Determine optimal retention time for a fragment peptide for optimal chromatography conditions including but not limited to gel electrophoresis, liquid chromatography, capillary electrophoresis, nano-reversed phase liquid chromatography, high performance liquid chromatography, or reverse phase high performance liquid chromatography

ii. Determine the mono isotopic mass of the peptide, the precursor charge state for each peptide, the precursor m/z value for each peptide, the m/z transition ions for each peptide, and the ion type of each transition ion for each fragment peptide in order to develop an SRM/MRM assay for each peptide.

iii. SRM/MRM assay can then be conducted using the information from (i) and (ii) on a triple quadrupole mass spectrometer where each peptide has a characteristic and unique SRM/MRM signature peak that precisely defines the unique SRM/MRM assay as performed on a triple quadrupole mass spectrometer

- b. Perform SRM/MRM analysis so that the amount of the fragment peptide of the DR5 protein that is detected, as a function of the unique SRM/MRM signature peak area from an SRM/MRM mass spectrometry analysis, can indicate both the relative and absolute amount of the DR5 protein in a particular protein lysate.

i. Relative quantitation may be achieved by:

1. Determining increased or decreased presence of the DR5 protein by comparing the SRM/MRM signature peak area from a given DR5 peptide detected in a Liquid Tissue™ lysate from one formalin fixed biological sample to the same SRM/MRM signature peak area of the same DR5 fragment peptide in at least a second, third, fourth or more

Liquid Tissue™ lysates from least a second, third, fourth or more formalin fixed biological samples.

- 5 2. Determining increased or decreased presence of the DR5 protein by comparing the SRM/MRM signature peak area from a given DR5 peptide detected in a Liquid Tissue™ lysate from one formalin fixed biological sample to SRM/MRM signature peak areas developed from fragment peptides from other proteins, in other samples derived from different and separate biological sources, where the SRM/MRM signature peak area comparison between the 2 samples for a peptide fragment are normalized to amount of protein analyzed in each sample.
- 10 3. Determining increased or decreased presence of the DR5 protein by comparing the SRM/MRM signature peak area for a given DR5 peptide to the SRM/MRM signature peak areas from other fragment peptides derived from different proteins within the same Liquid Tissue™ lysate from the formalin fixed biological sample in order to normalize changing levels of DR5 protein to levels of other proteins that do not change their levels of expression under various cellular conditions.
- 15 4. These assays can be applied to both unmodified fragment peptides and for modified fragment peptides of the DR5 protein, where the modifications include but are not limited to phosphorylation and/or glycosylation, and where the relative levels of modified peptides are determined in the same manner as determining relative amounts of unmodified peptides.
- 20 25 ii. Absolute quantitation of a given peptide may be achieved by comparing the SRM/MRM signature peak area for a given fragment peptide from the DR5 protein in an individual biological sample to the SRM/MRM signature peak area of an internal fragment peptide standard spiked into the protein lysate from the biological sample.
- 30 1. The internal standard is a labeled synthetic version of the fragment peptide from the DR5 protein that is being interrogated. This standard is spiked into a sample in known amounts, and the SRM/MRM signature peak area can be determined for both the internal fragment

peptide standard and the native fragment peptide in the biological sample separately, followed by comparison of both peak areas.

2. This can be applied to unmodified fragment peptides and modified fragment peptides, where the modifications include but are not limited to phosphorylation and/or glycosylation, and where the absolute levels of modified peptides can be determined in the same manner as determining absolute levels of unmodified peptides.

### III. Apply Fragment Peptide Quantitation to Cancer Diagnosis and Treatment

- a. Perform relative and/or absolute quantitation of fragment peptide levels of the DR5 protein and demonstrate that the previously-determined association, as well understood in the field of cancer, of DR5 protein expression to the stage/grade/status of cancer in patient tumor tissue is confirmed.

- b. Perform relative and/or absolute quantitation of fragment peptide levels of the DR5 protein individually, in combinations, or all simultaneously, and demonstrate correlation with clinical outcomes from different treatment strategies, wherein this correlation has already been demonstrated in the field or can be demonstrated in the future through correlation studies across cohorts of patients and tissue from those patients. Once either previously established correlations or correlations derived in the future are confirmed by this assay then the assay method can be used to determine optimal treatment strategy.

The information shown in Table 2 is necessary to develop an SRM/MRM assay for quantitation of the DR5 protein on a triplequadrupole mass spectrometer. Specific and unique characteristics about these DR5 peptides were developed by analysis of all DR5 peptides on an ion trap and/or triple quadrupole mass spectrometers. That information includes the monoisotopic mass of the peptide, its precursor charge state, the precursor m/z value, the transition m/z values of the precursor, and the ion types of each of the identified transitions. That information must be determined experimentally for each and every candidate SRM/MRM peptide directly in Liquid Tissue™ lysates from formalin fixed tissue; because, interestingly, not all peptides from the DR5 protein can be detected in such lysates using SRM/MRM as described herein, indicating that DR5 peptides not detected cannot be considered candidate peptides for developing an SRM/MRM assay for use in quantitating peptides/proteins directly in Liquid Tissue™ lysates from formalin fixed tissue.

Utilizing this information, quantitative SRM/MRM assays can be developed for the DR5 protein, and assessment of DR5 protein levels in tissues based on analysis of formalin fixed

patient-derived tumor tissue can provide diagnostic, prognostic, and therapeutically-relevant information about each particular cancer patient.

In one embodiment, this disclosure provides methods for measuring the level of the DR5 protein in a biological sample, comprising detecting and/or quantifying the amount of one or more modified or unmodified DR5 fragment peptides in a protein digest prepared from the biological sample using mass spectrometry; and calculating the level of modified or unmodified DR5 protein in the sample; and wherein the level is a relative level or an absolute level. In another embodiment, this disclosure provides a method for quantifying one or more DR5 fragment peptides, wherein the method comprises determining the amount of one or more of the DR5 fragment peptides in a biological sample by comparison to an added internal standard peptide of known amount, wherein each of the DR5 fragment peptides in the biological sample is compared to an internal standard peptide having the same amino acid sequence. In some embodiments the internal standard is an isotopically labeled internal standard peptide comprising one or more heavy stable isotopes selected from  $^{18}\text{O}$ ,  $^{17}\text{O}$ ,  $^{34}\text{S}$ ,  $^{15}\text{N}$ ,  $^{13}\text{C}$ ,  $^2\text{H}$  or combinations thereof.

The methods for measuring levels of the DR5 protein in a biological sample described herein (or fragment peptides as surrogates thereof) are useful as diagnostic indicators of cancer in a patient or subject. In one embodiment, the results from the measurements of levels of the DR5 protein may be employed to determine the diagnostic stage/grade/status of a cancer by correlating (e.g., comparing) the level of DR5 protein found in a tissue with the level of these proteins found in normal and/or cancerous or precancerous tissues.

**Embodiments:**

1. A method for measuring the amount of the DR5 protein in a biological sample, comprising detecting and/or quantifying the level of one or more modified or unmodified DR5 fragment peptides in a protein digest prepared from the biological sample using mass spectrometry; and calculating the level of modified or unmodified DR5 protein in the sample; and  
5 wherein the amount is a relative amount or an absolute amount.
2. The method of embodiment 0, further comprising the step of fractionating the protein digest prior to detecting and/or quantifying the level of one or more modified or unmodified DR5  
10 fragment peptides.
3. The method of embodiment 2, wherein the fractionating step is selected from the group consisting of gel electrophoresis, liquid chromatography, capillary electrophoresis, nano-reversed phase liquid chromatography, high performance liquid chromatography, and reverse phase high performance liquid chromatography.
- 15 4. The method of any of embodiments 1 to 3, wherein the protein digest of the biological sample is prepared by the Liquid Tissue™ protocol.
5. The method of any of embodiments 1 to 3, wherein the protein digest comprises a protease digest.
6. The method of embodiment 5, wherein the protein digest comprises a trypsin digest.
- 20 7. The method of any of embodiments 1 to 6, wherein the mass spectrometry comprises tandem mass spectrometry, ion trap mass spectrometry, triple quadrupole mass spectrometry, MALDI-TOF mass spectrometry, MALDI mass spectrometry, or time of flight mass spectrometry, or any combination thereof.
8. The method of embodiment 7, wherein the mode of mass spectrometry used is Selected  
25 Reaction Monitoring (SRM), Multiple Reaction Monitoring (MRM), or multiple Selected Reaction Monitoring (mSRM), or any combination thereof.
9. The method of any of embodiments 1 to 8, wherein the one or more modified or unmodified DR5 fragment peptides comprise different amino acid sequences independently selected from those set forth as SEQ ID NO:1, SEQ ID NO:2, and SEQ ID NO:3.
- 30 10. The method of any of embodiments 0 to 9, wherein the biological sample is a blood sample, a urine sample, a serum sample, an ascites sample, a sputum sample, lymphatic fluid, a saliva sample, a cell, or a solid tissue.

11. The method of embodiment 10, wherein the tissue is formalin fixed tissue.
12. The method of embodiment 10 or 11, wherein the tissue is paraffin embedded tissue.
13. The method of embodiment 10, wherein the tissue is obtained from a tumor.
14. The method of embodiment 13, wherein the tumor is a primary tumor.
- 5 15. The method of embodiment 13, wherein the tumor is a secondary tumor.
16. The method of any of embodiments 0 to 15, further comprising quantifying a modified or unmodified DR5 fragment peptide.
17. The method of embodiment 16, wherein quantifying a modified or unmodified fragment peptide comprises comparing the amount of one or more DR5 fragment peptides comprising an amino acid sequence of about 8 to about 45 amino acid residues of DR5 as shown in SEQ ID  
10 NO:1, SEQ ID NO:2, and SEQ ID NO:3 in one biological sample to the amount of the same DR5 fragment peptide in a different and separate biological sample.
18. The method of embodiment 17, wherein quantifying one or more modified or unmodified DR5 fragment peptides comprises determining the amount of the each of said one or more DR5  
15 fragment peptides in a biological sample by comparison to an added internal standard peptide of a known amount, wherein each of the DR5 fragment peptides in the biological sample is compared to an internal standard peptide having the same amino acid sequence.
19. The method of embodiment 18, wherein the internal standard peptide is an isotopically labeled peptide.
- 20 20. The method of embodiment 19, wherein the isotopically labeled internal standard peptide comprises one or more heavy stable isotopes selected from the group consisting of  $^{18}\text{O}$ ,  $^{17}\text{O}$ ,  $^{34}\text{S}$ ,  $^{15}\text{N}$ ,  $^{13}\text{C}$ , and  $^2\text{H}$ , or any combinations thereof.
21. The method of any of embodiments 1 to 20, wherein detecting and/or quantifying the amount of one or more modified or unmodified DR5 fragment peptides in the protein digest  
25 indicates the presence of modified or unmodified DR5 protein and an association with cancer in the subject.
22. The method of embodiment 21, further comprising correlating the results of detecting and/or quantifying amounts of one or more modified or unmodified DR5 fragment peptides, or the amount of the DR5 protein to the diagnostic stage/grade/status of the cancer.
- 30 23. The method of embodiment 22, wherein correlating the results of detecting and/or quantifying the amount of one or more modified or unmodified DR5 fragment peptides, or the

amount of the DR5 protein to the diagnostic stage/grade/status of the cancer is combined with detected and/or quantified amounts of other proteins, or peptides from other proteins, in a multiplex format to provide additional information about the diagnostic stage/grade/status of the cancer.

5 24. The method of any one of embodiments 1 to 23, further comprising selecting for the subject, from which the biological sample is obtained, a treatment based on the presence, absence, or amount of one or more DR5 fragment peptides or the amount of DR5 protein.

25. The method of any one of embodiments 1 to 24, further comprising administering to the patient from which the biological sample is obtained a therapeutically effective amount of a  
10 therapeutic agent, wherein the therapeutic agent and/or amount of the therapeutic agent administered is based upon the amount of one or more modified or unmodified DR5 fragment peptides or the amount of DR5 protein.

26. The method of embodiments 24 or 25, wherein the treatment or the therapeutic agent is directed to cancer cells expressing DR5 protein.

15 27. The method of any of embodiments 1 to 26, wherein the biological sample is formalin fixed tumor tissue that has been processed for quantifying the amount of one or more modified or unmodified DR5 fragment peptides employing the Liquid Tissue™ protocol and reagents.

28. The method of any of embodiments 1-27, wherein said one or more modified or unmodified DR5 fragment peptides is one, two, or more of the peptides in Table 1.

20 29. The method of any of embodiments 1-28, comprising quantifying the amount of the peptides in Table 2.

30. A composition comprising one, two, or three of the peptides in Table 1 or antibodies thereto, said composition optionally excluding one, two, three or more peptides of DR5 that are not peptides of SEQ ID NOs: 1, 2, and /or 3.

25 31. The composition of embodiment 30, comprising two, or three of the peptides of Table 2 or antibodies thereto.

It is to be understood that the description, specific examples, embodiments, and data, while indicating exemplary aspects, are given by way of illustration and are not intended to limit the present disclosure. Various changes and modifications within the present disclosure will  
30 become apparent to the skilled artisan from the discussion, detailed description, and data contained herein, and thus are considered part of the subject matter of this application. optionally excluding one, two, three or more peptides of DR5 that are not peptides of SEQ ID NOs: 1, 2, and /or 3.

**CLAIMS:**

1. A method for measuring the amount of the DR5 protein in a biological sample, comprising detecting and/or quantifying the level of one or more modified or unmodified DR5 fragment peptides in a protein digest prepared from the biological sample using mass spectrometry; and calculating the level of modified or unmodified DR5 protein in the sample; and

wherein the amount is a relative amount or an absolute amount.

2. The method of claim 0, further comprising the step of fractionating the protein digest prior to detecting and/or quantifying the level of one or more modified or unmodified DR5 fragment peptides.

3. The method of claim 2, wherein said fractionating step is selected from the group consisting of gel electrophoresis, liquid chromatography, capillary electrophoresis, nano-reversed phase liquid chromatography, high performance liquid chromatography, and reverse phase high performance liquid chromatography.

4. The method of claim 1, wherein said protein digest of said biological sample is prepared by the Liquid Tissue™ protocol.

5. The method of claim 1, wherein said protein digest comprises a protease digest.

6. The method of claim 5, wherein said protein digest comprises a trypsin digest.

7. The method of claim 1, wherein said mass spectrometry comprises tandem mass spectrometry, ion trap mass spectrometry, triple quadrupole mass spectrometry, MALDI-TOF mass spectrometry, MALDI mass spectrometry, or time of flight mass spectrometry, or any combination thereof.

8. The method of claim 7, wherein the mode of mass spectrometry used is Selected Reaction Monitoring (SRM), Multiple Reaction Monitoring (MRM), or multiple Selected Reaction Monitoring (mSRM), or any combination thereof.

9. The method of claim 1, wherein said one or more modified or unmodified DR5 fragment peptides comprise two or three different amino acid sequences independently selected from those set forth as SEQ ID NO:1, SEQ ID NO:2, and SEQ ID NO:3.

10. The method of claim 1, wherein said biological sample is a blood sample, a urine sample, a serum sample, an ascites sample, a sputum sample, lymphatic fluid, a saliva sample, a cell, or a solid tissue.

11. The method of claim 10, wherein said tissue is formalin fixed tissue.

12. The method of claim 10, wherein said tissue is paraffin embedded tissue.
13. The method of claim 10, wherein said tissue is obtained from a tumor.
14. The method of claim 13, wherein said tumor is a primary tumor.
15. The method of claim 13, wherein said tumor is a secondary tumor.
16. The method of claim 1, further comprising quantifying a modified or unmodified DR5 fragment peptide.
17. The method of claim 16, wherein quantifying a modified or unmodified fragment peptide comprises comparing the amount of one or more DR5 fragment peptides comprising an amino acid sequence of about 8 to about 45 amino acid residues of DR5 as shown in SEQ ID NO:1, SEQ ID NO:2, and SEQ ID NO:3 in one biological sample to the amount of the same DR5 fragment peptide in a different and separate biological sample.
18. The method of claim 17, wherein quantifying one or more modified or unmodified DR5 fragment peptides comprises determining the amount of the each of said DR5 fragment peptides in a biological sample by comparison to an added internal standard peptide of a known amount, wherein each of said DR5 fragment peptides in the biological sample is compared to an internal standard peptide having the same amino acid sequence.
19. The method of claim 18, wherein said internal standard peptide is an isotopically labeled peptide.
20. The method of claim 19, wherein said isotopically labeled internal standard peptide comprises one or more heavy stable isotopes selected from the group consisting of  $^{18}\text{O}$ ,  $^{17}\text{O}$ ,  $^{34}\text{S}$ ,  $^{15}\text{N}$ ,  $^{13}\text{C}$ , and  $^2\text{H}$ , or any combinations thereof.
21. The method of claim 1, wherein detecting and/or quantifying the amount of one or more modified or unmodified DR5 fragment peptides in said protein digest indicates the presence of modified or unmodified DR5 protein and an association with cancer in the subject.
22. The method of claim 21, further comprising correlating the results of detecting and/or quantifying amounts of one or more modified or unmodified DR5 fragment peptides, or the amount of the DR5 protein to the diagnostic stage/grade/status of the cancer.
23. The method of claim 22, wherein correlating the results of detecting and/or quantifying the amount of one or more modified or unmodified DR5 fragment peptides, or the amount of the DR5 protein to the diagnostic stage/grade/status of the cancer is combined with detected and/or quantified amounts of other proteins, or peptides from other proteins, in a multiplex format to provide additional information about the diagnostic stage/grade/status of the cancer.

24. The method of claim 1, further comprising selecting for the subject, from which the biological sample is obtained, a treatment based on the presence, absence, or amount of one or more DR5 fragment peptides or the amount of DR5 protein.
25. The method of claim 1, further comprising administering to the patient from which the biological sample is obtained a therapeutically effective amount of a therapeutic agent, wherein the therapeutic agent and/or amount of the therapeutic agent administered is based upon the amount of one or more modified or unmodified DR5 fragment peptides or the amount of DR5 protein.
26. The method of claim 24, wherein the treatment or the therapeutic agent is directed to cancer cells expressing DR5 protein.
27. The method of claim 1, wherein the biological sample is formalin fixed tumor tissue that has been processed for quantifying the amount of one or more modified or unmodified DR5 fragment peptides employing the Liquid Tissue™ protocol and reagents.
28. The method of claim 1, wherein said one or more modified or unmodified DR5 fragment peptides is one, two, or more of the peptides in Table 1.
29. The method of claim 1, comprising quantifying the amount of one or more or two or more of the peptides in Table 2.
30. A composition comprising one, two, or more of the peptides in Table 1 or antibodies thereto.
31. The composition of claim 30 comprising two, or three of the peptides of Table 2 or antibodies thereto.

专利名称(译)	MRM / SRM测定死亡受体5蛋白		
公开(公告)号	<a href="#">EP2758779A2</a>	公开(公告)日	2014-07-30
申请号	EP2012832855	申请日	2012-09-24
[标]申请(专利权)人(译)	爱科谱迅病理研究公司		
申请(专利权)人(译)	病理表达 , INC.		
当前申请(专利权)人(译)	病理表达 , INC.		
[标]发明人	KRIZMAN DAVID B HEMBROUGH TODD THYPARAMBIL SHEENO LIAO WEI LIAO		
发明人	KRIZMAN, DAVID, B. HEMBROUGH, TODD THYPARAMBIL, SHEENO LIAO, WEI-LIAO		
IPC分类号	G01N33/53 G01N33/68		
CPC分类号	G01N33/6848 G01N33/6863 G01N2333/70578 G01N2800/56 G01N2800/7028		
代理机构(译)	Bohmann , ARMIN K.		
优先权	61/538096 2011-09-22 US		
其他公开文献	EP2758779B1 EP2758779A4		
外部链接	<a href="#">Espacenet</a>		

#### 摘要(译)

提供了来自死亡受体5 ( DR5 ) 蛋白的那些肽的特定肽和衍生的电离特征，其特别有利于通过选择反应监测/多反应监测方法直接在已经在福尔马林中固定的生物样品中定量DR5蛋白。( SRM / MRM ) 质谱。这些生物样品是化学保存和固定的，其中生物样品选自用含甲醛的试剂/固定剂处理的组织和细胞，包括福尔马林固定的组织/细胞，福尔马林固定/石蜡包埋 ( FFPE ) 组织/细胞，FFPE组织块和来自这些区块的细胞和已经福尔马林固定和/或石蜡包埋的组织培养细胞。使用Liquid Tissue TM试剂和方案从生物样品制备蛋白质样品，并且通过SRM / MRM质谱法通过在蛋白质样品中定量，在Liquid Tissue TM样品中定量DR5蛋白质。至少一种或多种针对一种或多种DR5蛋白描述的肽。如果它们以修饰形式或未修饰形式存在，则可以定量这些肽。DR5肽的修饰形式的实例是肽序列内酪氨酸，苏氨酸，丝氨酸和/或其他氨基酸残基的磷酸化。